Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 10, 2023 08:00 ET | Source: BioAtla, Inc.

BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones

Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in a highly refractory population with additional patients enrolled BA3011...
December 22, 2022 08:00 ET | Source: BioAtla, Inc.

BioAtla to Participate in the 41st Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
November 08, 2022 08:00 ET | Source: BioAtla, Inc.

BioAtla to Participate in the Jefferies London Healthcare Conference

SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
November 04, 2022 09:08 ET | Source: BioAtla, Inc.

BioAtla Announces $65 Million Underwritten Offering of its Common Stock

SAN DIEGO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
November 03, 2022 16:01 ET | Source: BioAtla, Inc.

BioAtla Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with additional patients enrolledBA3011 Undifferentiated Pleomorphic Sarcoma (UPS) enrollment in...
October 27, 2022 08:00 ET | Source: BioAtla, Inc.

BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
August 09, 2022 16:05 ET | Source: BioAtla, Inc.

BioAtla Reports Second Quarter 2022 Financial Results And Highlights Recent Progress

Mecbotamab vedotin (BA3011) Phase 2 preliminary observations in Non-Small Cell Lung Carcinoma (NSCLC) supports advancing to the registrational stage of the study; anticipate full interim data set in...
August 03, 2022 08:00 ET | Source: BioAtla, Inc.

BioAtla to Participate in the 2022 BTIG Biotechnology Conference

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
August 02, 2022 08:00 ET | Source: BioAtla, Inc.

BioAtla to Announce Second Quarter 2022 Financial Results and Provide Business Highlights on August 9, 2022

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...
June 01, 2022 16:05 ET | Source: BioAtla, Inc.

BioAtla to Participate in 2022 Jefferies Global Healthcare Conference

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody...